GlassScriptPhysician profile
Maryann E Westbrook
NPI 1558738930
$12,652.21
in general payments reported to CMS, 2019-2025
36 companies · $2,198 in 2025
The $2,198 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,289 · 2022: $2,816 · 2023: $2,560 · 2024: $2,790 · 2025: $2,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,271 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,271.40 |
| Education | $275.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,829.88 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,551.80 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,395.19 | 2021-2025 | |
| Grifols USA, LLC | $1,163.46 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $798.78 | 2021-2025 | Trelegy Ellipta, Nucala |
| Pharming Healthcare, INC. | $749.74 | 2021-2025 | Ruconest |
| Csl Behring | $704.49 | 2021-2024 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $591.99 | 2021-2025 | Takhzyro, Hyqvia, Cuvitru |
| Amgen INC. | $530.98 | 2021-2025 | Tezspire |
| Optinose US, INC. | $428.22 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $311.29 | 2021-2024 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $305.78 | 2021-2025 | |
| Octapharma USA, INC. | $303.53 | 2021-2024 | Cutaquig |
| Genentech USA, INC. | $252.24 | 2021-2025 | Xolair |
| Aimmune Therapeutics, INC. | $238.60 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.90 | 2021-2022 | |
| Kaleo, INC. | $197.75 | 2021-2022 | |
| Abbvie INC. | $179.99 | 2022-2024 | |
| Pfizer INC. | $162.61 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $151.98 | 2023-2025 | |
| Incyte Corporation | $86.14 | 2022-2025 | Opzelura |
| Vifor Pharma, INC. | $72.97 | 2024-2025 | Zemaira |
| Leo Pharma INC. | $69.49 | 2022-2023 | Adbry |
| Blueprint Medicines Corporation | $58.09 | 2023-2024 | Ayvakit |
| Lilly USA, LLC | $44.63 | 2025 | Ebglyss |
| Mylan Specialty L.P. | $40.46 | 2021 | |
| Cycle Pharmaceuticals INC | $33.67 | 2024 | Sajazir |
| Merck Sharp & Dohme LLC | $33.31 | 2021-2023 | |
| Adma Biomanufacturing LLC | $25.53 | 2021 | |
| Ionis Pharmaceuticals, INC. | $23.06 | 2025 | Dawnzera |
| Teva Pharmaceuticals USA, INC. | $19.20 | 2021 | |
| Verona Pharma, INC. | $19.19 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $16.12 | 2025 | Xhance |
| Dermavant Sciences, INC. | $14.79 | 2024 | Vtama |
| Hikma Pharmaceuticals USA | $14.75 | 2023 | Ryaltris |
| Organon LLC | $12.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryann Westbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.